Zealand Pharma A/S

Zealand Pharma is a biotechnology company. Co. is engaged in the discovery development and commercialization of peptide-based medicines. Co.'s pipeline comprises two implementation areas: Cardio-metabolic diseases and Other indications. The Cardio-metabolic diseases area includes medicines for diabetes and obesity treatment, such as Lyxumia (Lixisenatide), Lyxumia/Lantus, ZP2929 and Danegaptide. The Other indications area are ZP1848, Elsiglutide and ZP1480 (ABT-719) drugs for inflammatory bowel disease, chemotherapy-induced diarrhea and acute kidney injury treatment.
  • TickerZLDPF
  • ISINDK0060257814
  • ExchangePink OTC Markets
  • SectorPharmaceuticals & Biotechnology
  • CountryUnited States
Eric Le Berrigaud

ZEALAND: Model Update and FV upgrade - Contacts | BUY | DKK293 vs. DKK228 (+20%)

ZEALAND - BUY | DKK293 vs. DKK228 (+20%) Model Update and FV upgrade - Contacts Increasingly looking like a 2-franchise company The acquisition of Valeritas is a strategic move Dasiglucagon: a pipeline in a drug? GI-tract disorders as a second franchise Conclusion and new FV

Zealand Pharma AS: 1 director bought

A director at Zealand Pharma AS bought 1,570 shares at 243.600DKK and the significance rating of the trade was 70/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of ...

Zealand Pharma AS: 1 director bought

A director at Zealand Pharma AS bought 1,570 shares at 243.600DKK and the significance rating of the trade was 70/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of ...

Eric Le Berrigaud

ZEALAND: Model Update and FV upgrade - Contacts | BUY | DKK293 vs. DKK228 (+20%)

ZEALAND - BUY | DKK293 vs. DKK228 (+20%) Model Update and FV upgrade - Contacts Increasingly looking like a 2-franchise company The acquisition of Valeritas is a strategic move Dasiglucagon: a pipeline in a drug? GI-tract disorders as a second franchise Conclusion and new FV

Eric Le Berrigaud

ZEALAND: Opportunistic and pragmatic move to prepare for dasiglucagon US launch | BUY | DKK260 vs. DKK217 (+1%)

ZEALAND - BUY | DKK260 vs. DKK217 (+1%) Opportunistic and pragmatic move to prepare for dasiglucagon US launch Candidate to acquire Valeritas in full or parts Saving time at a reasonable price FV adjustment is independent of this transaction

Eric Le Berrigaud

ZEALAND Proposed acquisition of Chapter-11-protected US company:

Zealand announced this morning that it has submitted a bid to acquire �substantially all assets� of Valeritas, a US-based commercial-stage company which is commercializing an insulin delivery device called V-Go, a all-in-one basal-bolus option for adults that is used like a daily patch and eliminates multiple shots. In December, the company announced that it was facing a temporary disruption in supply of its product, making it unable to ship it any longer. Valeritas said it had cash until February 2020 and as it was expected supply disruption to continue, it said it would explore all strategic...

Feasibility Study Results in December to be a Catalyst for this Junior

Feasibility Study Results in December to be a Catalyst for this Junior